medigraphic.com
ISSN 2500-7106 (Digital)
ISSN 0123-2576 (Impreso)
Medicina & Laboratorio

2017, Número 01-02

<< Anterior Siguiente >>

Medicina & Laboratorio 2017; 23 (01-02)


Hiperparatiroidismo primario

Builes-Montaño CE

Idioma: Español
Referencias bibliográficas: 73
Paginas: 45-63
Archivo PDF: 523.81 Kb.


RESUMEN

El hiperparatiroidismo primario es uno de los trastornos endocrinos más frecuentes, caracterizado por la producción no controlada de la paratohormona. Esta condición clínica puede ser completamente asintomática o mostrarse con manifestaciones que ponen en peligro la vida de quien la padece. La gran variedad en las formas de presentación y algunos errores frecuentes en la interpretación de los resultados de las pruebas disponibles para su diagnóstico hacen de esta alteración un reto para el médico. Un hiperparatiroidismo no diagnosticado, y en consecuencia no tratado, puede tener consecuencias nefastas para los pacientes como deterioro en la función renal, que puede llevar a requerir una terapia de reemplazo renal, osteoporosis, que se puede acompañar de fracturas por fragilidad y cambios neurocognitivos que pueden socavar la calidad de vida de las personas. Por lo anterior, es fundamental conocer y comprender este trastorno, así como reconocer e interpretar adecuadamente las ayudas diagnósticas para poder proponer un plan de tratamiento adecuado que, afortunadamente en la mayoría de los casos, lleva a la curación del trastorno.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Bandeira L, Bilezikian J. Primary Hyperparathyroidism. F1000Res 2016; 5.

  2. Albright F, Aub JC, Bauer W. Hyperparathyroidism: A common and polymorphic condition as illustrated by seventeen proved cases from one clinic. JAMA 1934; 102: 1276-1287.

  3. Cusano NE, Silverberg SJ, Bilezikian JP. Normocalcemic primary hyperparathyroidism. J Clin Densitom 2013; 16: 33-39.

  4. Keating FR, Jr. Diagnosis of primary hyperparathyroidism. Clinical and laboratory aspects. JAMA 1961; 178: 547- 555.

  5. Eufrazino C, Veras A, Bandeira F. Epidemiology of Primary Hyperparathyroidism and its Non-classical Manifestations in the City of Recife, Brazil. Clin Med Insights Endocrinol Diabetes 2013; 6: 69-74.

  6. Gasser RW. Clinical aspects of primary hyperparathyroidism: clinical manifestations, diagnosis, and therapy. Wien Med Wochenschr 2013; 163: 397-402.

  7. Wermers RA, Khosla S, Atkinson EJ, Achenbach SJ, Oberg AL, Grant CS, et al. Incidence of primary hyperparathyroidism in Rochester, Minnesota, 1993-2001: an update on the changing epidemiology of the disease. J Bone Miner Res 2006; 21: 171-177.

  8. Lassen T, Friis-Hansen L, Rasmussen AK, Knigge U, Feldt-Rasmussen U. Primary hyperparathyroidism in young people. When should we perform genetic testing for multiple endocrine neoplasia 1 (MEN-1)? J Clin Endocrinol Metab 2014; 99: 3983-3987.

  9. Roizen J, Levine MA. A meta-analysis comparing the biochemistry of primary hyperparathyroidism in youths to the biochemistry of primary hyperparathyroidism in adults. J Clin Endocrinol Metab 2014; 99: 4555-4564.

  10. Cohen J, Gierlowski TC, Schneider AB. A prospective study of hyperparathyroidism in individuals exposed to radiation in childhood. Jama 1990; 264: 581-584.

  11. Wermers RA, Kearns AE, Jenkins GD, Melton LJ, 3rd. Incidence and clinical spectrum of thiazide-associated hypercalcemia. Am J Med 2007; 120: 911.e919-915.

  12. McHenry CR, Lee K. Lithium therapy and disorders of the parathyroid glands. Endocr Pract 1996; 2: 103-109.

  13. Liu JM, Cusano NE, Silva BC, Zhao L, He XY, Tao B, et al. Primary Hyperparathyroidism: A Tale of Two Cities Revisited - New York and Shanghai. Bone Res 2013; 1: 162-169.

  14. Yeh MW, Ituarte PH, Zhou HC, Nishimoto S, Liu IL, Harari A, et al. Incidence and prevalence of primary hyperparathyroidism in a racially mixed population. J Clin Endocrinol Metab 2013; 98: 1122-1129.

  15. Bilezikian JP, Brandi ML, Eastell R, Silverberg SJ, Udelsman R, Marcocci C, et al. Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the Fourth International Workshop. J Clin Endocrinol Metab 2014; 99: 3561-3569.

  16. Rejnmark L, Amstrup AK, Mollerup CL, Heickendorff L, Mosekilde L. Further insights into the pathogenesis of primary hyperparathyroidism: a nested case-control study. J Clin Endocrinol Metab 2013; 98: 87-96.

  17. Vignali E, Viccica G, Diacinti D, Cetani F, Cianferotti L, Ambrogini E, et al. Morphometric vertebral fractures in postmenopausal women with primary hyperparathyroidism. J Clin Endocrinol Metab 2009; 94: 2306-2312.

  18. Cipriani C, Biamonte F, Costa AG, Zhang C, Biondi P, Diacinti D, et al. Prevalence of kidney stones and vertebral fractures in primary hyperparathyroidism using imaging technology. J Clin Endocrinol Metab 2015; 100: 1309-1315.

  19. Kulak CA, Bandeira C, Voss D, Sobieszczyk SM, Silverberg SJ, Bandeira F, et al. Marked improvement in bone mass after parathyroidectomy in osteitis fibrosa cystica. J Clin Endocrinol Metab 1998; 83: 732-735.

  20. Bandeira F, Griz L, Caldas G, Bandeira C, Freese E. From mild to severe primary hyperparathyroidism: The Brazilian experience. Arq Bras Endocrinol Metabol 2006; 50: 657- 663.

  21. Silverberg SJ, Clarke BL, Peacock M, Bandeira F, Boutroy S, Cusano NE, et al. Current issues in the presentation of asymptomatic primary hyperparathyroidism: proceedings of the Fourth International Workshop. J Clin Endocrinol Metab 2014; 99: 3580-3594.

  22. Sorensen MD, Duh QY, Grogan RH, Tran TC, Stoller ML. Urinary parameters as predictors of primary hyperparathyroidism in patients with nephrolithiasis. J Urol 2012; 187: 516-521.

  23. Evan AE, Lingeman JE, Coe FL, Miller NL, Bledsoe SB, Sommer AJ, et al. Histopathology and surgical anatomy of patients with primary hyperparathyroidism and calcium phosphate stones. Kidney Int 2008; 74: 223-229.

  24. Bilezikian JP. Management of acute hypercalcemia. N Engl J Med 1992; 326: 1196-1203.

  25. Rubin MR, Maurer MS, McMahon DJ, Bilezikian JP, Silverberg SJ. Arterial stiffness in mild primary hyperparathyroidism. J Clin Endocrinol Metab 2005; 90: 3326-3330.

  26. Walker MD, Fleischer J, Rundek T, McMahon DJ, Homma S, Sacco R, et al. Carotid vascular abnormalities in primary hyperparathyroidism. J Clin Endocrinol Metab 2009; 94: 3849-3856.

  27. Bilezikian JP, Khan AA, Potts JT, Jr. Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the third international workshop. J Clin Endocrinol Metab 2009; 94: 335-339.

  28. Yu N, Leese GP, Donnan PT. What predicts adverse outcomes in untreated primary hyperparathyroidism? The Parathyroid Epidemiology and Audit Research Study (PEARS). Clin Endocrinol (Oxf) 2013; 79: 27-34.

  29. Espiritu RP, Kearns AE, Vickers KS, Grant C, Ryu E, Wermers RA. Depression in primary hyperparathyroidism: prevalence and benefit of surgery. J Clin Endocrinol Metab 2011; 96: E1737-1745.

  30. Kahal H, Aye M, Rigby AS, Sathyapalan T, England RJ, Atkin SL. The effect of parathyroidectomy on neuropsychological symptoms and biochemical parameters in patients with asymptomatic primary hyperparathyroidism. Clin Endocrinol (Oxf) 2012; 76: 196-200.

  31. Maruani G, Hertig A, Paillard M, Houillier P. Normocalcemic primary hyperparathyroidism: evidence for a generalized target-tissue resistance to parathyroid hormone. J Clin Endocrinol Metab 2003; 88: 4641-4648.

  32. Eastell R, Brandi ML, Costa AG, D’Amour P, Shoback DM, Thakker RV. Diagnosis of asymptomatic primary hyperparathyroidism: proceedings of the Fourth International Workshop. J Clin Endocrinol Metab 2014; 99: 3570-3579.

  33. Martinez I, Saracho R, Montenegro J, Llach F. The importance of dietary calcium and phosphorous in the secondary hyperparathyroidism of patients with early renal failure. Am J Kidney Dis 1997; 29: 496-502.

  34. Cusano N, Silverberg S, Bilezikian J. Chapter 22 - Normocalcemic PHPT. The Parathyroids (Third Edition). San Diego: Academic Press; 2015: 331-339.

  35. Amaral LM, Queiroz DC, Marques TF, Mendes M, Bandeira F. Normocalcemic versus Hypercalcemic Primary Hyperparathyroidism: More Stone than Bone? J Osteoporos 2012; 2012: 128352.

  36. Scholz DA, Purnell DC. Asymptomatic primary hyperparathyroidism. 10-year prospective study. Mayo Clin Proc 1981; 56: 473-478.

  37. Fitzpatrick LA. Chapter 26 - Acute Primary Hyperparathyroidism A2 - Bilezikian, John P. The Parathyroids (Third Edition). San Diego: Academic Press; 2015: 401-408.

  38. Cundy T, Darby AJ, Berry HE, Parsons V. Bone metabolism in acute parathyroid crisis. Clin Endocrinol (Oxf) 1985; 22: 787-793.

  39. Caron P, Simonds WF, Maiza JC, Rubin M, Cantor T, Rousseau L, et al. Nontruncated amino-terminal parathyroid hormone overproduction in two patients with parathyroid carcinoma: a possible link to HRPT2 gene inactivation. Clin Endocrinol (Oxf) 2011; 74: 694-698.

  40. Robertson WG, Marshall RW. Calcium measurements in serum and plasma--total and ionized. CRC Crit Rev Clin Lab Sci 1979; 11: 271-304.

  41. Hossein-nezhad A, Holick MF. Vitamin D for health: a global perspective. Mayo Clin Proc 2013; 88: 720-755.

  42. Tucci JR. Vitamin D therapy in patients with primary hyperparathyroidism and hypovitaminosis D. Eur J Endocrinol 2009; 161: 189-193.

  43. Thakker RV. Familial and Hereditary Forms of Primary Hyperparathyroidism A2. En: Bilezikian JP, Marcus R, Levine MA, Marcocci C, Silverberg SJ, Potts JT, eds. The Parathyroids (ed 3a). California, Estados Unidos: Academic Press; 2015: 341-363.

  44. Starker LF, Fonseca AL, Carling T, Udelsman R. Minimally invasive parathyroidectomy. Int J Endocrinol 2011; 2011: 206502.

  45. Noussios G, Anagnostis P, Natsis K. Ectopic parathyroid glands and their anatomical, clinical and surgical implications. Exp Clin Endocrinol Diabetes 2012; 120: 604-610.

  46. Kunstman JW, Kirsch JD, Mahajan A, Udelsman R. Clinical review: Parathyroid localization and implications for clinical management. J Clin Endocrinol Metab 2013; 98: 902-912.

  47. Cheung K, Wang TS, Farrokhyar F, Roman SA, Sosa JA. A meta-analysis of preoperative localization techniques for patients with primary hyperparathyroidism. Ann Surg Oncol 2012; 19: 577-583.

  48. Smith RB, Evasovich M, Girod DA, Jorgensen JB, Lydiatt WM, Pagedar NA, et al. Ultrasound for localization in primary hyperparathyroidism. Otolaryngol Head Neck Surg 2013; 149: 366-371.

  49. Hetrakul N, Civelek AC, Stagg CA, Udelsman R. In vitro accumulation of technetium-99m-sestamibi in human parathyroid mitochondria. Surgery 2001; 130: 1011-1018.

  50. Froberg AC, Valkema R, Bonjer HJ, Krenning EP. 99mTc-tetrofosmin or 99mTc-sestamibi for double-phase parathyroid scintigraphy? Eur J Nucl Med Mol Imaging 2003; 30: 193-196.

  51. Leslie WD, Dupont JO, Bybel B, Riese KT. Parathyroid 99mTc-sestamibi scintigraphy: dual-tracer subtraction is superior to double-phase washout. Eur J Nucl Med Mol Imaging 2002; 29: 1566-1570.

  52. Moralidis E. Radionuclide parathyroid imaging: a concise, updated review. Hell J Nucl Med 2013; 16: 125-133.

  53. Wei WJ, Shen CT, Song HJ, Qiu ZL, Luo QY. Comparison of SPET/CT, SPET and planar imaging using 99mTc-MIBI as independent techniques to support minimally invasive parathyroidectomy in primary hyperparathyroidism: A meta- analysis. Hell J Nucl Med 2015; 18: 127-135.

  54. Kluijfhout WP, Vorselaars WM, Vriens MR, Borel Rinkes IH, Valk GD, de Keizer B. Enabling minimal invasive parathyroidectomy for patients with primary hyperparathyroidism using Tc-99m-sestamibi SPECT-CT, ultrasound and first results of (18)F-fluorocholine PET-CT. Eur J Radiol 2015; 84: 1745-1751.

  55. Guerin C, Lowery A, Gabriel S, Castinetti F, Philippon M, Vaillant-Lombard J, et al. Preoperative imaging for focused parathyroidectomy: making a good strategy even better. Eur J Endocrinol 2015; 172: 519-526.

  56. Berner AM, Haroon A, Nowosinska E, Offiah C, Luqman M, Newell M, et al. Localization of parathyroid disease with ‘sequential multiphase and dual-tracer’ technique and comparison with neck ultrasound. Nucl Med Commun 2015; 36: 45-52.

  57. Starker LF, Mahajan A, Bjorklund P, Sze G, Udelsman R, Carling T. 4D parathyroid CT as the initial localization study for patients with de novo primary hyperparathyroidism. Ann Surg Oncol 2011; 18: 1723-1728.

  58. Mahajan A, Starker LF, Ghita M, Udelsman R, Brink JA, Carling T. Parathyroid four-dimensional computed tomography: evaluation of radiation dose exposure during preoperative localization of parathyroid tumors in primary hyperparathyroidism. World J Surg 2012; 36: 1335-1339.

  59. Michel L, Dupont M, Rosiere A, Merlan V, Lacrosse M, Donckier JE. The rationale for performing MR imaging before surgery for primary hyperparathyroidism. Acta Chir Belg 2013; 113: 112-122.

  60. Nael K, Hur J, Bauer A, Khan R, Sepahdari A, Inampudi R, et al. Dynamic 4D MRI for Characterization of Parathyroid Adenomas: Multiparametric Analysis. AJNR Am J Neuroradiol 2015; 36: 2147-2152.

  61. Michaud L, Balogova S, Burgess A, Ohnona J, Huchet V, Kerrou K, et al. A Pilot Comparison of 18F-fluorocholine PET/CT, Ultrasonography and 123I/99mTc-sestaMIBI Dual-Phase Dual-Isotope Scintigraphy in the Preoperative Localization of Hyperfunctioning Parathyroid Glands in Primary or Secondary Hyperparathyroidism: Influence of Thyroid Anomalies. Medicine (Baltimore) 2015; 94: e1701.

  62. Kunstman JW, Udelsman R. Superiority of minimally invasive parathyroidectomy. Adv Surg 2012; 46: 171-189.

  63. Naveh-Many T, Rahamimov R, Livni N, Silver J. Parathyroid cell proliferation in normal and chronic renal failure rats. The effects of calcium, phosphate, and vitamin D. J Clin Invest 1995; 96: 1786-1793.

  64. Jorde R, Szumlas K, Haug E, Sundsfjord J. The effects of calcium supplementation to patients with primary hyperparathyroidism and a low calcium intake. Eur J Nutr 2002; 41: 258-263.

  65. Marcocci C, Bollerslev J, Khan AA, Shoback DM. Medical management of primary hyperparathyroidism: proceedings of the fourth International Workshop on the Management of Asymptomatic Primary Hyperparathyroidism. J Clin Endocrinol Metab 2014; 99: 3607-3618.

  66. Grey A, Lucas J, Horne A, Gamble G, Davidson JS, Reid IR. Vitamin D repletion in patients with primary hyperparathyroidism and coexistent vitamin D insufficiency. J Clin Endocrinol Metab 2005; 90: 2122-2126.

  67. Stewart ZA, Blackford A, Somervell H, Friedman K, Garrett-Mayer E, Dackiw AP, et al. 25-hydroxyvitamin D deficiency is a risk factor for symptoms of postoperative hypocalcemia and secondary hyperparathyroidism after minimally invasive parathyroidectomy. Surgery 2005; 138: 1018-1025; discussion 1025-1016.

  68. Khan AA, Bilezikian JP, Kung AW, Ahmed MM, Dubois SJ, Ho AY, et al. Alendronate in primary hyperparathyroidism: a double-blind, randomized, placebo-controlled trial. J Clin Endocrinol Metab 2004; 89: 3319-3325.

  69. Khan AA, Bilezikian JP, Kung A, Dubois SJ, Standish TI, Syed ZA. Alendronate therapy in men with primary hyperparathyroidism. Endocr Pract 2009; 15: 705-713.

  70. Zanocco K, Angelos P, Sturgeon C. Cost-effectiveness analysis of parathyroidectomy for asymptomatic primary hyperparathyroidism. Surgery 2006; 140: 874-881; discussion 881-872.

  71. Shoback DM, Bilezikian JP, Turner SA, McCary LC, Guo MD, Peacock M. The calcimimetic cinacalcet normalizes serum calcium in subjects with primary hyperparathyroidism. J Clin Endocrinol Metab 2003; 88: 5644-5649.

  72. Peacock M, Bolognese MA, Borofsky M, Scumpia S, Sterling LR, Cheng S, et al. Cinacalcet treatment of primary hyperparathyroidism: biochemical and bone densitometric outcomes in a five-year study. J Clin Endocrinol Metab 2009; 94: 4860-4867.

  73. Khan A, Bilezikian J, Bone H, Gurevich A, Lakatos P, Misiorowski W, et al. Cinacalcet normalizes serum calcium in a double-blind randomized, placebo-controlled study in patients with primary hyperparathyroidism with contraindications to surgery. Eur J Endocrinol 2015; 172: 527-535.




2020     |     www.medigraphic.com